Physician profile
Dat T DO
NPI 1962508325
$19,895.49
in general payments reported to CMS, 2019-2025
38 companies · $3,385 in 2025
The $3,385 reported for 2025 was more than what 77% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,767 · 2020: $786 · 2021: $1,802 · 2022: $2,694 · 2023: $3,386 · 2024: $4,075 · 2025: $3,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,714.59 |
| Education | $132.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,528.82 | 2019-2025 | Gallant, Jot Dx, Aveir |
| Janssen Pharmaceuticals, INC | $2,053.24 | 2019-2024 | Xarelto |
| Abiomed | $1,942.63 | 2019-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $1,681.62 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $1,392.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $916.88 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $760.52 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $583.99 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $537.26 | 2022-2025 | |
| Medtronic, INC. | $503.90 | 2021-2024 | In.Pact Admiral |
| Shockwave Medical, INC | $498.07 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $490.42 | 2019-2024 | Avvigo Guidance System |
| Medtronic Vascular, INC. | $436.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $417.21 | 2019-2025 | |
| Biotronik INC. | $380.50 | 2025 | Biomonitor, Amvia Edge, Pamira |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $337.19 | 2019-2023 | |
| Edwards Lifesciences Corporation | $326.72 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.99 | 2019-2023 | Lifevest |
| Cardiovascular Systems INC. | $238.79 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $217.45 | 2022-2025 | Verquvo, Capvaxive |
| Atricure, INC. | $175.97 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax |
| Akcea Therapeutics, INC. | $152.39 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $131.81 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $117.59 | 2024 | Opsumit, Uptravi |
| Lilly USA, LLC | $114.65 | 2019 | |
| Cook Medical LLC | $107.91 | 2019 | |
| Vifor Pharma, INC. | $99.21 | 2019 | |
| Pfizer INC. | $91.89 | 2019-2021 | |
| Astellas Pharma US INC | $91.84 | 2019 | |
| Esperion Therapeutics, INC. | $78.33 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $63.66 | 2024-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $34.55 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $31.01 | 2019 | |
| Heartflow, INC. | $21.30 | 2025 | |
| Mylan Specialty L.P. | $18.28 | 2019 | |
| Scpharmaceuticals INC. | $17.80 | 2023 | |
| Daiichi Sankyo INC. | $14.14 | 2022 | |
| Chiesi USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dat DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.